152
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Genotoxicity of Casiopeina III-Ea in mouse bone marrow cells

, , &
Pages 333-338 | Received 15 Mar 2016, Accepted 08 Aug 2016, Published online: 26 Oct 2016
 

Abstract

Casiopeina III-Ea® (Cas III-Ea®) is a chelated copper complex with antineoplastic activity that is capable of reducing tumor size and inducing antiproliferative and apoptotic effects. However, little is known about its in vivo genotoxic effects. Therefore, this study evaluated two cytogenetic and two proliferative parameters 24 h after the administration of Casiopeina III-Ea® to male CD-1 mice. Three doses of Cas III-Ea® were administered by intraperitoneal injections of 1.69, 3.39 and 6.76 mg/kg (corresponding to 1/8, 1/4 and 1/2 of LD50, respectively). A reduction in the mitotic index (MI) and an increased numbers of cells with structural chromosomal aberrations (SCA) were detected. Additionally, a low but significant increase in the frequency of sister chromatid exchange (SCE) was observed at the highest dose. Changes in the DNA replication index (RI) were not observed. These results indicate that Casiopeina III-Ea® shows cytotoxic and clastogenic activity in bone marrow cells from treated mice.

Acknowledgements

We thank to Dra. Ma. Elena Bravo-Gómez for the synthesis of Cas III-Ea®, and MVZ. Adriana Altamirano Bautista and MVZ. Roman Hernández Meza for its technical support in the care and handling of animals.

Declaration of interest

The author’s declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article. This work was supported by CONACYT-REDES 87806.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.